Jane Street’s Eledon Pharmaceuticals ELDN Stock Holding History

Jane Street’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,700	Closed	-$35.5K	–	11416
2025 Q3	$35.5K	Buy	+13,700	New	+$40.1K	﹤0.01%	10426

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Jane Street's ELDN Position: Q1 2026 in Review

Jane Street sold out of Eledon Pharmaceuticals (ELDN) in Q1 2026, closing a stake of 489,376 shares — an estimated $1.15M sold.

Jane Street first reported a position in ELDN in Q2 2019 and held it in 7 quarters. The position peaked at $761K in Q1 2025. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

Jane Street reported no remaining Eledon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jane Street sold 489,376 Eledon Pharmaceuticals shares in Q1 2026, an estimated $1.15M.
Jane Street first reported a position in Eledon Pharmaceuticals in Q2 2019 and held it in 7 quarters.
Jane Street's Eledon Pharmaceuticals position peaked at $761K in Q1 2025.
121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.